Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: cancer therapeutics - BeOne Medicines

Next Previous
Drug Profile

Research programme: cancer therapeutics - BeOne Medicines

Alternative Names: BGB-108; Brodomain containing protein 4 inhibitors - BeOne Medicines; EGFR T790 mutation inhibitors - BeOne Medicines; iOnc monoclonal antibody - BeOne Medicines; iONC small molecule therapeutic - BeOne Medicines; KRAS protein inhibitors - BeOne Medicines; PD-1 monoclonal antibody - BeOne Medicines; PD-L1 monoclonal antibody - BeOne Medicines

Latest Information Update: 14 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BeiGene
  • Developer BeOne Medicines
  • Class Antineoplastics; Monoclonal antibodies; Small molecules
  • Mechanism of Action BRD4 protein inhibitors; Epidermal growth factor inhibitors; HAVCR2 protein modulators; Immunomodulators; KRAS protein inhibitors; Programmed cell death 1 receptor modulators; Programmed cell death-1 ligand-1 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 28 Dec 2018 No recent reports of development identified for preclinical development in Cancer in China (Parenteral)
  • 09 Aug 2018 BeiGene plans a phase I/II trial in combination with tislelizumab for Solid tumours in
  • 07 Jan 2018 BeiGene in-licenses H2L2 transgenic mouse platform from Harbour BioMed

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top